Yaser Heshmati, Ph.D.
About Yaser Heshmati, Ph.D.
Yaser Heshmati, Ph.D., is a Scientist II at Tessera Therapeutics, focusing on innovative therapeutics for hematologic disorders. He specializes in target-specific acute protein degradation techniques and has a strong background in medical genetics and hematology.
Work at Tessera Therapeutics
Yaser Heshmati serves as a Scientist II at Tessera Therapeutics, a position he has held since 2022. In this role, he focuses on developing innovative therapeutics for hematologic disorders. His work involves utilizing both ex vivo and in vivo models to explore potential treatment options. Tessera Therapeutics is located in Somerville, Massachusetts, where Heshmati contributes to advancing the field of gene therapy.
Previous Research Experience
Prior to his current role, Yaser Heshmati worked as a Postdoctoral Researcher at Harvard Medical School from 2019 to 2022. His research during this time focused on hematology and oncology, contributing to various projects in these fields. He also held a postdoctoral position at Karolinska University Hospital in Stockholm, Sweden, for five months in 2018, and at Boston Children's Hospital from 2019 to 2022. These experiences provided him with a solid foundation in medical research.
Education and Expertise
Yaser Heshmati earned his Ph.D. in Medical Genetics and Hematology/Oncology from Karolinska Institutet, where he studied from 2012 to 2018. He also holds an MSc in Human Genetics from the University of Social Welfare and Rehabilitation Sciences in Tehran, completed from 2005 to 2008. His undergraduate degree is a BSc in Molecular Genetics from Shahid Chamran University of Ahvaz, obtained from 2001 to 2005. His educational background supports his specialization in target-specific acute protein degradation techniques.
Research Focus and Contributions
Yaser Heshmati engages in therapeutic gene writing aimed specifically at hematological disorders. His research interests include the development of innovative therapeutic strategies that address the complexities of these conditions. His expertise in target-specific acute protein degradation techniques plays a significant role in his contributions to the field of hematology.